1428063-43-7

Basic information

• Product Name: N-(2,4-dichlorophenyl)-6-nitroquinazolin-4-amine
• Synonyms: N-(2,4-dichlorophenyl)-6-nitroquinazolin-4-amine
• CAS NO: 1428063-43-7
• Molecular Weight: 335.149
• Mol File: 1428063-43-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(2,4-dichlorophenyl)-6-nitroquinazolin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4-dichlorophenyl)-6-nitroquinazolin-4-amine(1428063-43-7)
• EPA Substance Registry System: N-(2,4-dichlorophenyl)-6-nitroquinazolin-4-amine(1428063-43-7)

Safety Data

• Hazardous Substances Data: 1428063-43-7(Hazardous Substances Data)

Upstream product

• 22363-16-2 ethyl N-(2-cyano-4-nitrophenyl)formimidate 
• 554-00-7 2,4-Dichloroaniline 
• 17420-30-3 5-nitroanthranilonitrile 

Downstream Products

• 1428064-06-5 C₂₂H₂₀Cl₂N₄O₄ 
• 1428063-66-4 N⁴-(2,4-dichlorophenyl)-4,6-quinazolinediamine 

Relevant articles and documents

4-Arylamino-6-nitroquinazolines: Synthesis and their activities against neglected disease leishmaniasis

4-Arylamino-6-nitroquinazolines (2-25) were synthesized and evaluated for their leishmanicidal activities against Leishmania major promastigotes in vitro with IC50 values Combining double low line 1.87-61.48 μM. Among the twenty four synthetic derivatives, 4-[4′-(methylsulfanyl)phenyl]amino-6-nitroquinazoline (21), and 4-(2′-methoxyphenyl)amino-6-nitroquinazoline (8) showed excellent antileishmanial activities with IC50 values 1.87 ± 0.31 and 4.37 ± 0.02 μM, respectively, more active than the standard drug, pentamidine (IC50 Combining double low line 5.09 ± 0.09 μM). Compound 16 (IC50 Combining double low line 6.53 ± 0.21 μM) displayed an activity comparable to the standard. Compounds 15 (IC50 Combining double low line 9.04 ± 0.03 μM), 18 (IC50 Combining double low line 12.28 ± 0.18 μM), 14 (IC50 Combining double low line 19.87 ± 0.22 μM), and 5 (IC50 Combining double low line 24.03 ± 2.71 μM) also showed good activities.

Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors

4-Anilino-6-substituted-quinazolines were designed, synthesized and evaluated for EGFR-TK and tumor growth inhibitory activities. The target compounds were designed with enamine ester or urea moieties appended at the C-6 of quinazoline as additional hydrogen bond acceptor functions. Most of the synthesized compounds displayed potent EGFR-TK inhibitory activity at 10 μM and the 6-ureido-anilinoquinazoline derivative 7a showed IC50 value of 0.061 μM. Moreover, six compounds were tested by National Cancer Institute (NCI), USA for their anti-proliferative activity at 10 μM in full NCI 60 cell panel. Compound 7a was further assayed for five dose molar ranges in full NCI 60 cell panel and exhibited remarkable growth inhibitory activity pattern against Non-Small Cell Lung Cancer EKVX (GI50 = 0.37 μM), NCI-H322M (GI50 = 0.36 μM), Renal Cancer A498 (GI50 = 0.46 μM), TK-10 (GI50 = 0.99 μM) and Breast Cancer MDA-MB-468 (GI50 = 1.096 μM) which are of high EGFR expression. Docking study was performed for the active compounds into ATP binding site of EGFR-TK which showed similar binding mode to gefitinib and additional binding with Cys-773 at the gatekeeper of EGFR-TK enzyme.